Stabilizing The Heparin Marketplace

	Ability to Supply Market		Safe Supply of Heparin
	Navigating Supply Chain		APP Commitments

In February 2008, an increase in the number of reported severe allergic reactions to heparin led other manufacturers to recall the majority of their heparin products as the U.S. Food and Drug Administration (FDA) worked to determine the cause. As a result, heparin supply within the wholesaler pipeline, hospitals and clinics was severely challenged.

In close collaboration with the FDA's Drug Shortage Division, APP Pharmaceuticals (APP) stepped in and dramatically increased manufacturing capacity for heparin and assured healthcare professionals that the company would take every step necessary to meet supply needs in the U.S. for this life-saving drug. (Click here to learn more about the importance of heparin to the healthcare system)

Through significant investments in infrastructure and staffing in manufacturing and quality assurance, regulatory, customer service, medical information, distribution, and capacity expansion, APP met the supply requirements of the U.S. heparin market.